Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.80 |
| ▸ | GAPDH | P04406 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.80 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | PI4KA | P42356 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.80 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160215 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL9737249 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL6721572 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12150762 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12300475 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL969049 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12030590 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL6712774 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL21418729 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL30531775 | 1.00 | ADORA3 (0.80) | ADORA3ADORA1DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372725-B1 | VIRICIDES, ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2002-04-16 | — | — | US | claimed |
| JP-1029394-A | — | — | None | — | — | JP | disclosed |
| JP-3284691-A | — | — | None | — | — | JP | disclosed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-4504970-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | New England Biolabs, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| US-6372725-B1 | VIRICIDES, ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2002-04-16 | — | — | US | disclosed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| US-5658890-A | INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-19 | — | — | US | disclosed |
| JP-H03284691-A | ANTIVIRAL NUCLEOSIDE | ASAHI GLASS CO LTD | 1991-12-16 | — | — | JP | disclosed |
| JP-S6429394-A | PURINE NUCLEOSIDE DERIVATIVE | ASAHI GLASS CO LTD | 1989-01-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | ADORA3 342/4885ADORA1 364/4885DPP4 1763/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | ADORA3 1034/4885ADORA1 992/4885DPP4 358/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885DPP4 749/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | ADORA3 464/4885ADORA1 539/4885DPP4 443/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 304/4885ADORA1 493/4885DPP4 750/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA3 3807/4885ADORA1 4046/4885DPP4 4471/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885DPP4 749/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885DPP4 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.